A study on the relationship of circadian rhythm with Homocysteine and Lipoprotein-associated phospholipase A2 in coronary heart disease

The recently Effects of small dose of Folic Acid on Lipoprotein-associated Phospholipase A2 and Systolic Blood Pressure Variability in Patients with Coronary Heart Disease Complicated with Hyperhomocysteinemia

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000033203

Enrollment

Unknown

Registered

2020-05-23

Start date

2016-04-29

Completion date

Unknown

Last updated

2020-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary artery disease

Interventions

Group A:The patients were performed coronary heart disease (CHD) standardized medication, including antiplatelet, beta blockers, angiotensin II receptor blockers and statins et al.

Group B:taking folic acid 0.4 mg

Group C:taking folic acid 0.8 mg

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: The patients with CHD (Coronary artery stenosis greater than or equal to 50 percent Cleared by Coronary angiography or coronary CT angiography) complicated with hyperhomocysteinemia (>10umol/l) hospitalized in department of cardiovascular medicine, Yue Bei People's Hospital Affiliated to Shantou University.

Exclusion criteria

Exclusion criteria: taking folic acid or B vitamin drugs in nearly three months, liver and kidney function abnormal obviously, blood system diseases, acute or chronic infection.

Design outcomes

Primary

Measure	Time frame
homocysteine;Lipoprotein-associated phospholipase A2;Systolic Blood Pressure Variability;ApoA;	—

Secondary

Measure	Time frame
TC;TG;ApoB;Lp (a);LDL-C;HDL-C;	—

Countries

China

Contacts

Public ContactXiangyang Liu

Yuebei People's Hospital

longliu0714@sina.com+86 13553640790

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026